Burden of severe respiratory syncytial virus disease among 33-35 weeks' gestational age infants born during multiple respiratory syncytial virus seasons

Pediatric Infectious Disease Journal

Volumn 36, Issue 2, 2017, Pages 160-167

  Anderson, Evan J ^a   Carbonell Estrany, Xavier ^b   Blanken, Maarten ^c   Lanari, Marcello ^d   Sheridan Pereira, Margaret ^e   Rodgers Gray, Barry ^f   Fullarton, John ^f   Rouffiac, Elisabeth ⁱ   Vo, Pamela ⁱ   Notario, Gerard ^g   Campbell, Fiona ⁱ   Paes, Bosco ^h  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Imola Hospital   (Italy)

^e Tallaght and Coombe Women's and Infant's University Hospital   (Ireland)

^f Strategen Limited   (United Kingdom)

^g ABBVIE INC   (United States)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ NONE

Author keywords

Lower respiratory tract infections; Moderate late preterm infants; Respiratory syncytial virus; Respiratory syncytial virus hospitalization

Indexed keywords

ARTICLE; ARTIFICIAL VENTILATION; CHILD HOSPITALIZATION; DISEASE SEVERITY; EMBASE; GESTATIONAL AGE; HOSPITAL ADMISSION; HOSPITALIZED INFANT; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INCIDENCE; INFANT; LENGTH OF STAY; LOWER RESPIRATORY TRACT INFECTION; MEDLINE; NEONATAL INTENSIVE CARE UNIT; NORTHERN HEMISPHERE; OBSERVATIONAL STUDY; OXYGEN THERAPY; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESOURCE MANAGEMENT; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEASONAL VARIATION; SYSTEMATIC REVIEW; HOSPITALIZATION; META ANALYSIS; NEWBORN; NEWBORN DISEASE; STATISTICS AND NUMERICAL DATA;

GESTATIONAL AGE; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INFANT, PREMATURE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 84991457618     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001377     Document Type: Article

References (46)

1. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545-1555.
2. Jain S, Williams DJ, Arnold SR, et al; CDC EPIC Study Team. Community acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372:835-845.
3. Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr. 2003;143(5 suppl):S133-S141.
4. Figueras-Aloy J, Carbonell-Estrany X, Quero J; IRIS Study Group. Casecontrol study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004;23:815-820.
5. Ambrose CS, Anderson EJ, Simões EA, et al. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis. Pediatr Infect Dis J. 2014;33:576-582.
6. Shefali-Patel D, Paris MA, Watson F, et al. RSV hospitalisation and healthcare utilisation in moderately prematurely born infants. Eur J Pediatr. 2012;171:1055-1061.
7. Forbes ML, Hall CB, Jackson A, et al. Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of life. J Med Econ. 2010;13:136-141.
8. Palmer L, Hall CB, Katkin JP, et al. Respiratory outcomes, utilization and costs 12 months following a respiratory syncytial virus diagnosis among commercially insured late-preterm infants. Curr Med Res Opin. 2011;27:403-412.
9. Carbonell-Estrany X, Pérez-Yarza EG, García LS, et al; IRIS (Infección Respiratoria Infantil por Virus Respiratorio Sincitial) Study Group. Longterm burden and respiratory effects of respiratory syncytial virus hospitalization in preterm infants - the SPRING study. PLoS One. 2015;10:e0125422.
10. Bacharier LB, Cohen R, Schweiger T, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2012;130:91-100.e3.
11. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, et al; IRIS Study Group. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008;27:788-793.
12. Carbonell-Estrany X, Quero J; IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J. 2001;20:874-879.
13. Sheridan-Pereira M, Murphy J, Sloan J, et al. Respiratory syncytial virus preterm (32-36 completed weeks of gestation) risk estimation measure for RSV hospitalization in Ireland: A prospective study. Pediatr Infect Dis J. 2016;35:19-24.
14. Notario G, Vo P, Gooch K, et al. Respiratory syncytial virus-related hospitalization in premature infants without bronchopulmonary dysplasia: subgroup efficacy analysis of the IMpact-RSV trial by gestational age group. Pediatric Health Med Ther. 2014;5:43-48.
15. Blanken MO, Rovers MM, Molenaar JM, et al; Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368:1791-1799.
16. Figueras Aloy J, Carbonell Estrany X; Comité de Estándares de la SENeo. [Update of recommendations on the use of palivizumab as prophylaxis in RSV infections]. An Pediatr (Barc). 2015;82:199.e1-199.e2.
17. Bollani L, Baraldi E, Chirico G, et al; Italian Society of Neonatology. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital J Pediatr. 2015;41:97.
18. Association of Scientific Medical Societies (DE). Leitlinie zur Prophylaxe von schweren Erkrankungen durch Respiratory Syncytial Virus (RSV) bei Risikokindern. AWMF-LL 048-012 28. Oktober 2012.
19. Robinson JL, Le Saux N; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Preventing hospitalizations for respiratory syncytial virus infection. Paediatr Child Health. 2015;20:321-333.
20. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee.. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:e620-e638.
21. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537.
22. Feltes TF, Cabalka AK, Meissner HC, et al; Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532-540.
23. Langley GF, Anderson LJ. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J. 2011;30:510-517.
24. Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23:806-814.
25. Blanken MO, Koffijberg H, Nibbelke EE, et al; Dutch RSV Neonatal Network. Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study. PLoS One. 2013;8:e59161.
26. Lanari M, Prinelli F, Adorni F, et al; Study Group of Italian Society of Neonatology on Risk Factors for RSV Hospitalization. Risk factors for bronchiolitis hospitalization during the first year of life in a multicenter Italian birth cohort. Ital J Pediatr. 2015;41:40.
27. Straňák Z, Saliba E, Kosma P, et al. Predictors of RSV LRTI hospitalization in infants born at 33 to 35 weeks gestational age: a large multinational study (PONI). PLoS One. 2016;11:e0157446.
28. Díez-Domingo J, Pérez-Yarza EG, Melero JA, et al. Social, economic, and health impact of the respiratory syncytial virus: a systematic search. BMC Infect Dis. 2014;14:544.
29. Makari D, Hoopes JM, White N. Impact of RSV: implications for managed care. Manag Care. 2009;18(1 suppl 2):2-7.
30. Andabaka T, Nickerson JW, Rojas-Reyes MX, et al. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013:CD006602.
31. Carbonell-Estrany X, Lázaro y de Mercado P. Health economics and RSV. Paediatr Respir Rev. 2009;10(suppl 1):12-13.
32. Lanctôt KL, Masoud ST, Paes BA, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. Curr Med Res Opin. 2008;24:3223-3237.
33. Leidy NK, Margolis MK, Marcin JP, et al. The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery. Pediatrics. 2005;115:1536-1546.
34. Miedema CJ, Kors AW, Tjon A Ten WE, et al. Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in The Netherlands. Pediatr Infect Dis J. 2001;20:160-163.
35. Leader S, Yang H, DeVincenzo J, et al. Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants. Value Health. 2003;6:100-106.
36. Robbins JM, Tilford JM, Gillaspy SR, et al. Parental emotional and time costs predict compliance with respiratory syncytial virus prophylaxis. Ambul Pediatr. 2002;2:444-448.
37. Colin AA, McEvoy C, Castile RG. Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks' gestational age. Pediatrics. 2010;126:115-128.
38. Kugelman A, Colin AA. Late preterm infants: near term but still in a critical developmental time period. Pediatrics. 2013;132:741-751.
39. Weigl JA, Puppe W, Schmitt HJ. Incidence of respiratory syncytial viruspositive hospitalizations in Germany. Eur J Clin Microbiol Infect Dis. 2001;20:452-459.
40. Fjaerli HO, Farstad T, Bratlid D. Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993-2000: a population-based retrospective study. BMC Pediatr. 2004;4:25.
41. Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virusassociated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132:e341-e348.
42. Panozzo CA, Fowlkes AL, Anderson LJ. Variation in timing of respiratory syncytial virus outbreaks: lessons from national surveillance. Pediatr Infect Dis J. 2007;26(11 suppl):S41-S45.
43. Haynes AK, Prill MM, Iwane MK, et al; Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus-United States, July 2012-June 2014. MMWR Morb Mortal Wkly Rep. 2014;63:1133-1136.
44. Schuh S, Freedman S, Coates A, et al. Effect of oximetry on hospitalization in bronchiolitis: a randomized clinical trial. JAMA. 2014;312:712-718.
45. King D, Dicks RA, Wacogne ID. Infants with artificially elevated pulse oximetry levels less likely to be hospitalised during an episode of mild to moderate bronchiolitis. Arch Dis Child Educ Pract Ed. 2016;101: 162-163.
46. Baraldi E, Lanari M, Manzoni P, et al. Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants. Ital J Pediatr. 2014;40:65.